Evidence map›Paper›PMID 32929654›Full record

ArticleMolecular biology reports2020

MicroRNA-203a regulates pancreatic β cell proliferation and apoptosis by targeting IRS2.

Xianlan Duan, Lian Zhao, Wancun Jin, Qinxin Xiao, Yani Peng, Gan Huang, Xia Li, Sonia DaSilva-Arnold, Haibo Yu, Zhiguang Zhou

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Xianlan DuanDepartment of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Lian ZhaoDepartment of Gastroenterology, Central South University, The Third Xiangya Hospital, Changsha, 410013, Hunan, China.
Wancun JinDepartment of Echocardiography, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Qinxin XiaoDepartment of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Yani PengDepartment of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Gan HuangDepartment of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Xia LiDepartment of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Sonia DaSilva-ArnoldDepartment of Obstetrics and Gynecology, Center for Abnormal Placentation, Hackensack University Medical Center, Hackensack, NJ, USA.
Haibo YuDepartment of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. yuhaibo616@csu.edu.cn.ORCID http://orcid.org/0000-0002-0645-3663
Zhiguang ZhouDepartment of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Central South University · CNHackensack University Medical Center · US

Funding

National Natural Science Youth Foundation of China 81402272National Natural Science Youth Foundation of China 81702797Natural Science Foundation of Hunan Province 2018JJ2213Natural Science Foundation of Hunan Province 2018JJ3745New Xiangya Talent Project Funding of the Third Xiangya Hospital of Central South University JY201627
6 · The paper itself

Abstract

The main pathogenesis of type 1 diabetes mellitus (T1DM) is autoimmune-mediated apoptosis of pancreatic islet β cells. We sought to characterize the function of microRNA-203a (miR-203a) on pancreatic islet β cell proliferation and apoptosis. In situ hybridization was used to detect the expression of miR-203a in islet β cells in normal and hyperglycaemic non-obese diabetic (NOD) mice. Cell proliferation was measured by cell counting kit eight and cell apoptosis was detected using flow cytometry. Insulin receptor substrate 2 (IRS2/Irs2) was determined to be a direct target of miR-203a by Luciferase reporter assay. We detected the effects of miR-203a overexpression or inhibition on proliferation and apoptosis of IRS2-overexpressing or IRS2-knockdown MIN6 cells respectively, and preliminarily explored the downstream targets of the IRS2 pathway. NOD mice model was used to detect miR-203a inhibitor treatment for diabetes. Our experiment showed miR-203a was upregulated in pancreatic β cells of hyperglycaemic NOD mice. Elevated miR-203a expression inhibited the proliferation and promoted the apoptosis of MIN6 cells. IRS2/Irs2 is a novel target gene directly regulated by miR-203a and miR-203a overexpression downregulated the expression of IRS2. Irs2 silencing reduced cell proliferation and increased apoptosis. Irs2 overexpression could abolish the pro-apoptotic and anti-proliferative effects of miR-203a on MIN6 cells. Hyperglycemia in newly hyperglycemic NOD mice was under control after treatment with miR-203a inhibitor. Our study suggests that miR-203a regulates pancreatic β cell proliferation and apoptosis by targeting IRS2, treatment with miR-203a inhibitors and IRS2 might provide a new therapeutic strategy for T1DM.

Indexed as

ApoptosisCell ProliferationAnimalsCell LineFemaleHyperglycemiaInsulin Receptor Substrate ProteinsInsulin-Secreting CellsMiceMice, Inbred NODMicroRNAsInsulin Receptor Substrate ProteinsIrs2 protein, mouseMicroRNAsMIRN203 microRNA, mouseInsulin receptor substrate 2microRNA-203aPancreatic β cellType 1 diabetes mellitus

Identifiers

PMID32929654
OpenAlexW3086443223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.